A Randomized, Controlled Pilot Study of Autologous CD34+ Cell Therapy for Critical Limb Ischemia | Zendy

Douglas W. Losordo | Zendy; Melina R. Kibbe | Zendy; Farrell O. Mendelsohn | Zendy; William A. Marston | Zendy; Vickie R. Driver | Zendy; Mel J. Sharafuddin | Zendy; Victoria Teodorescu | Zendy; Bret N. Wiechmann | Zendy; Charles S. Thompson | Zendy; Larry W. Kraiss | Zendy; Teresa L. Carman | Zendy; Suhail Dohad | Zendy; Paul P. Huang | Zendy; Candice Junge | Zendy; Kenneth Story | Zendy; Tara Weistroffer | Zendy; Tina Thorne | Zendy; Meredith Millay | Zendy; John Paul Runyon | Zendy; Robert M. Schainfeld | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

A Randomized, Controlled Pilot Study of Autologous CD34+ Cell Therapy for Critical Limb Ischemia

Author(s) -

Douglas W. Losordo,

Melina R. Kibbe,

Farrell O. Mendelsohn,

William A. Marston,

Vickie R. Driver,

Mel J. Sharafuddin,

Victoria Teodorescu,

Bret N. Wiechmann,

Charles S. Thompson,

Larry W. Kraiss,

Teresa L. Carman,

Suhail Dohad,

Paul P. Huang,

Candice Junge,

Kenneth Story,

Tara Weistroffer,

Tina Thorne,

Meredith Millay,

John Paul Runyon,

Robert M. Schainfeld

Publication year - 2012

Publication title -

circulation cardiovascular interventions

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.621

H-Index - 95

eISSN - 1941-7632

pISSN - 1941-7640

DOI - 10.1161/circinterventions.112.968321

Subject(s) - medicine , critical limb ischemia , randomized controlled trial , stem cell therapy , ischemia , cell therapy , limb ischemia , surgery , vascular disease , stem cell , transplantation , arterial disease , biology , genetics

Critical limb ischemia portends a risk of major amputation of 25% to 35% within 1 year of diagnosis. Preclinical studies provide evidence that intramuscular injection of autologous CD34+ cells improves limb perfusion and reduces amputation risk. In this randomized, double-blind, placebo-controlled pilot study, we evaluated the safety and efficacy of intramuscular injections of autologous CD34+ cells in subjects with moderate or high-risk critical limb ischemia, who were poor or noncandidates for surgical or percutaneous revascularization (ACT34-CLI).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research